Urogen Pharma (URGN) – Analysts’ Weekly Ratings Changes

Urogen Pharma (NASDAQ: URGN) has recently received a number of price target changes and ratings updates:

• 5/18/2026 – Urogen Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
• 5/11/2026 – Urogen Pharma had its price target raised by HC Wainwright from $40.00 to $45.00. They now have a “buy” rating on the stock.
• 5/11/2026 – Urogen Pharma is now covered by LADENBURG THALM/SH SH. They set a “buy” rating and a $43.00 price target on the stock.
• 5/7/2026 – Urogen Pharma had its price target raised by Oppenheimer Holdings, Inc. from $34.00 to $40.00. They now have an “outperform” rating on the stock.
• 4/24/2026 – Urogen Pharma was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 4/20/2026 – Urogen Pharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/10/2026 – Urogen Pharma is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $40.00 price target on the stock.
• 3/31/2026 – Urogen Pharma had its “buy” rating reaffirmed by D. Boral Capital. They now have a $33.00 price target on the stock.

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.